Skip to content
OpenCapital
Get started

Beam Therapeutics BEAM Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
-$749K—

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$3.49B+24.5%
Enterprise value$3.45B+51.2%
P/S21.3×-22.8×

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%—
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%—
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Beam Therapeutics's increase (decrease) in contract liabilities and current deferred income?
Beam Therapeutics (BEAM) reported increase (decrease) in contract liabilities and current deferred income of -$6.36M in Q1 2026.
How has Beam Therapeutics's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
Beam Therapeutics's increase (decrease) in contract liabilities and current deferred income increased by 14.9% year-over-year, from -$7.47M to -$6.36M.
What is the long-term trend for Beam Therapeutics's increase (decrease) in contract liabilities and current deferred income?
Over 3 years (2021 to 2025), Beam Therapeutics's increase (decrease) in contract liabilities and current deferred income has grown at a -27.1% compound annual growth rate (CAGR), from $348.92M to -$135.42M.